Which patients with mCRPC on ADT + advanced anti-AR do you treat with bisphosphonates or denosumab?   

Men with bone-metastatic CRPC face a relatively high rate of fractures due to bone loss as a result of potent AR inhibition and ongoing ADT but also due to lytic and sclerotic bone metastases which create focal weakening of the bone matrix despite the pathologic bone formation. The fracture rate was...

Agree with @Andrew J. Armstrong. For the radiation oncology audience, the cause of the higher number of deaths in the radium-223 group in ERA-223 fully remains unknown.  Indeed, fractures are associated with increased mortality in various clinical settings; however, as a PI of ERA-223, mos...